Imagion Biosystems has announced a notification to ineligible shareholders regarding the renounceable pro-rata offer of 28 October 2019.
Read the notification.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal